Home » Stocks » Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc. (ALNY)

Stock Price: $137.43 USD 0.74 (0.54%)
Updated Aug 13, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 15.94B
Revenue (ttm) 345.18M
Net Income (ttm) -846.17M
Shares Out 115.97M
EPS (ttm) -7.51
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 13, 2020
Last Price $137.43
Previous Close $136.69
Change ($) 0.74
Change (%) 0.54%
Day's Open 138.11
Day's Range 136.78 - 141.40
Day's Volume 391,563
52-Week Range 73.32 - 167.33

More Stats

Market Cap 15.94B
Enterprise Value 14.33B
Earnings Date (est) Oct 29, 2020
Ex-Dividend Date n/a
Shares Outstanding 115.97M
Float 115.00M
EPS (basic) -7.58
EPS (diluted) -7.51
FCF / Share -7.58
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 5.44M
Short Ratio 6.71
Short % of Float 5.07%
Beta 1.80
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 46.17
PB Ratio 12.26
Revenue 345.18M
Operating Income -923.39M
Net Income -846.17M
Free Cash Flow -871.24M
Net Cash 1.61B
Net Cash / Share 13.89
Gross Margin 56.40%
Operating Margin -267.51%
Profit Margin -245.10%
FCF Margin -252.40%
ROA -18.95%
ROE -53.61%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (21)

Buy 13
Overweight 1
Hold 7
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$161.40*
(17.44% upside)
Low
90.0
Current: $137.43
High
202.0
Target: 161.40
*Average 12-month price target from 20 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue22074.9189.9147.1641.1050.5647.1766.7382.76100
Revenue Growth193.36%-16.69%90.66%14.75%-18.72%7.2%-29.31%-19.37%-17.28%-
Gross Profit19573.1189.9147.1641.1050.5647.1766.7382.76100
Operating Income-939-815-500-425-296-405-92.94-129-54.82-44.07
Net Income-886-761-491-410-290-360-89.23-106-57.65-43.52
Shares Outstanding10910190.5585.6083.9974.2861.5550.2942.4142.04
Earnings Per Share-8.11-7.57-5.42-4.79-3.45-4.85-1.45-2.11-1.36-1.04
Operating Cash Flow-278-563-383-308-189-166-68.66-116-87.07-84.34
Capital Expenditures-140-127-104-64.56-12.95-8.96-4.01-8.35-1.29-4.73
Free Cash Flow-419-690-487-372-202-175-72.66-124-88.36-89.07
Cash & Equivalents1,5361,0841,6916271,081697246123146233
Total Debt30430.0030.00150------
Net Cash / Debt1,2321,0541,6614771,081697246123146233
Assets2,3951,5751,9951,2631,3871,080421288282393
Liabilities956273228343122143150153164235
Book Value1,4391,3021,7669201,265936270134118158
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Alnylam Pharmaceuticals, Inc.
Country United States
Employees 1,323
CEO John M. Maraganore

Stock Information

Ticker Symbol ALNY
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: ALNY
IPO Date May 28, 2004

Description

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP). In addition, the company is developing givosiran for the treatment of patients with AHP; lumasiran for the treatment of primary hyperoxaluria type 1, or PH1; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; and vutrisiran for the treatment of ATTR amyloidosis. Alnylam Pharmaceuticals, Inc. has strategic alliances primarily with Sanofi Genzyme; The Medicines Company; Ionis Pharmaceuticals, Inc.; and Regeneron Pharmaceuticals, Inc., as well as collaboration with Vir Biotechnology, Inc. to advance RNAi therapeutics for the treatment of coronavirus infection, including COVID-19. It also has a collaboration and license agreement with Dicerna Pharmaceuticals, Inc. to develop and commercialize investigational ribonucleic acid interference therapeutics for the treatment of alpha-1 antitrypsin deficiency-associated liver disease, as well as Vir Biotechnology, Inc. to develop and commercialize RNAi therapeutics. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.